The Pandemic Influenza drugs in development market research report provides comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pandemic Influenza. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Pandemic Influenza - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pandemic Influenza and features dormant and discontinued products.

GlobalData tracks 23 drugs in development for Pandemic Influenza by 23 companies/universities/institutes. The top development phase for Pandemic Influenza is preclinical with 14 drugs in that stage. The Pandemic Influenza pipeline has 23 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pandemic Influenza pipeline products market are: Arcturus Therapeutics, Sanofi and Cocrystal Pharma.

The key targets in the Pandemic Influenza pipeline products market include Hemagglutinin, Hemagglutinin HA (HA), and Hemagglutinin 1 (H1).

The key mechanisms of action in the Pandemic Influenza pipeline product include Sirtuin (SIRT or EC 2.3.1.) Activator with one drug in Preclinical. The Pandemic Influenza pipeline products include seven routes of administration with the top ROA being Intramuscular and nine key molecule types in the Pandemic Influenza pipeline products market including Subunit Vaccine, and Small Molecule.

Pandemic Influenza overview

A flu pandemic is characterized by the worldwide spread of a novel flu A virus, and it occurs when this emerging virus has the capability to efficiently infect and transmit among humans, affecting a large population with limited immunity. Such pandemics are marked by the ability of the new influenza A virus to spread easily from person to person. The most recent instance of a flu pandemic took place in 2009 with the emergence of a novel influenza A (H1N1) virus.

For a complete picture of Pandemic Influenza’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.